Autres langues HOOKIPA Pharma Inc.

Actions

HOOK

US43906K2096

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Après clotûre 01:58:44
6,6 ^USD	+11,49 %		6,685	+1,29 %

01/07	HOOKIPA Pharma annonce que le premier patient a été traité dans le cadre de l'étude sur le traitement du VIH	MT
01/07	HOOKIPA Pharma Inc. annonce que la première personne a reçu un dosage dans le cadre de l'essai clinique de phase 1b du HB-500 pour le traitement du VIH	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split	08/07
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	02/07
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	01/07
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	01/07
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	01/07
Squamous Cell Carcinoma Pipeline 2024 \| FDA Approvals, Clinical Trials, Therapies, MOA, ROA \| Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna	19/06
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting	04/06
HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting	04/06
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting	30/05
HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting	23/05
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting	23/05
HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab	25/04
HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab	25/04
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	24/04
HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	24/04
HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)	17/04
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	16/04
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration	10/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HOOKIPA Pharma Inc.

Actions

HOOK

US43906K2096

Autres langues

Filtres